Produktname:tert-butyl (4S,5R)-4-formyl-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate
IUPAC Name:tert-butyl (4S,5R)-4-formyl-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate
- CAS：163625-46-5
- Molekulare Formel：C17H23NO4
- Reinheit：95%+
- Katalognummer：CM1032621
- Molekulargewicht：305.37
| Packungseinheit |
Verfügbarer Vorrat |
Preis($) |
Menge |
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:163625-46-5
- Molekulare Formel:C17H23NO4
- Schmelzpunkt:-
- SMILES-Code:CC1(N([C@@H]([C@H](O1)C2=CC=CC=C2)C=O)C(=O)OC(C)(C)C)C
- Dichte:
- Katalognummer:CM1032621
- Molekulargewicht:305.37
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Oxazolidines
- Oxazolidines are five-membered ring compounds consisting of three carbons, nitrogen and oxygen. Oxygen and nitrogen are in the 1 and 3 positions, respectively. Oxazolidine is in general yellow or slightly yellow, alkaline liquid or solid, easily hydrolyzed by water or alcohol. It is insoluble in water (or hydrolyzed); soluble in benzene and chloroform. Oxazolidine derivatives are five-membered cyclic compounds containing at least one oxygen and nitrogen in their molecular structure. Oxazolidine derivatives are known to possess various therapeutic activities, such as anticancer and antibiotic properties.
Column Infos
- Vibegron
- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of OBGEMSA (vibegron under the international non-proprietary name) for the symptomatic treatment of adult patients with overactive bladder syndrome (OAB).
Vibegron is a novel, potent, and selective human beta-3 adrenergic receptor (β3-AR) agonist. Beta receptors are found throughout the body, but β3-ARs are predominantly found on human detrusor smooth muscle. β3-ARs agonists bind to and activate beta-3 receptors on the detrusor muscle, leading to relaxation of the detrusor muscle to increase vesical capacity and to reduce OAB symptoms.
Suche 
+86 21 5895 0110 
